Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Chan

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2014
Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancerTarek M Abdel-Fatah, Graham Ball, Andrew H S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerSara M Tolaney, Arlene Chan, Katarina Petrakova, et al.
Breast (Edinburgh, Scotland)|October 16, 2020
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 studyPeter A Fasching, J Thaddeus Beck, Arlene Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialWolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
Future Oncology (London, England)|May 30, 2019
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancerHiroji Iwata, Norikazu Masuda, Sung-Bae Kim, et al.
The Oncologist|August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trialsAndrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
The Lancet. Oncology|May 1, 2020
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialSara M Tolaney, Andrew M Wardley, Stefania Zambelli, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2014
Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancerTarek M Abdel-Fatah, Graham Ball, Andrew H S Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerSara M Tolaney, Arlene Chan, Katarina Petrakova, et al.
Breast (Edinburgh, Scotland)|October 16, 2020
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 studyPeter A Fasching, J Thaddeus Beck, Arlene Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trialWolfgang Eiermann, Tadeusz Pienkowski, John Crown, et al.
Future Oncology (London, England)|May 30, 2019
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancerHiroji Iwata, Norikazu Masuda, Sung-Bae Kim, et al.
The Oncologist|August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trialsAndrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.
International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
The Lancet. Oncology|May 1, 2020
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialSara M Tolaney, Andrew M Wardley, Stefania Zambelli, et al.
Pageof 9